MOG and myeloid sarcoma: However, the prevalence range is wide, with around 95% in MS, and for example 16.4% in neuromyelitis optica [32], 6–17% in myelin oligodendrocyte glycoprotein antibody-associated disease [33], 25% in Sjögren’s syndrome [34], and 29–58% in acute disseminated encephalomyelitis [35, 36].